How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Ultomiris is given by a doctor or nurse, not picked up at a pharmacy.

What to do

  1. Ask your care team or your plan what you’d pay before your visit.

Your care team and your insurance decide which product you get.

Compare every option

Brand name

Ultomiris, the original

Cash priceAsk the pharmacy
Ways to save on Ultomiris

The maker’s card

Alexion OneSource CoPay Program

Savings card from Alexion (AstraZeneca Rare Disease)

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0

Sign up on ultomiris.com 

Or call 1-888-765-4747.

In the maker’s words

“Pay as low as $0 in out-of-pocket costs…”

From the maker’s offer on ultomiris.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized generic

There isn’t one.

Not soldThere isn’t one

Regular generic

Ultomiris is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

Not soldAsk the pharmacy

What it’s used for

What the FDA label says

ULTOMIRIS is a complement inhibitor indicated for:

  • the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
  • the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
  • the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
  • the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive.
  • to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether ULTOMIRIS slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Source: the FDA label for Ultomiris (Alexion Pharmaceuticals Inc.), October 29, 2026. Full label on DailyMed 

Good to know

  • “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
  • Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.